Associate Editor, Ophthalmology Times
ARVO 2024: Predicting 3-year myopia control efficacy from 1-year data
May 11th 2024At this year's ARVO meeting in Seattle, Washington, the Eye Care Network spoke with Noel Brennan, MScOptom, PhD. The clinical research fellow at Johnson and Johnson shared highlights from his presentation on myopia control and predictive modeling.
Read More
At this year's ARVO meeting in Seattle, Washington, Dolly Chang, MD, PhD, presented data on the early fluid reduction in patients with diabetic macular edema, and how that correlates with 1-year outcome with a deep learning-based retina segmentation tool using the Phase 2 BOULEVARD trial.
Read More
ARVO 2024: Impact of switching when using an aflibercept biosimilar
May 9th 2024SriniVas R Sadda, MD, presented "Post Hoc Analysis of a Phase 3 Trial on SB15 (Proposed Aflibercept Biosimilar): Assessment on Pre-to-Post Switching Efficacy and Safety in Neovascular Age-related Macular Degeneration."
Read More
ARVO 2024: A study on multi-ingredient oral supplement for dry eye symptoms and tear volume
May 7th 2024Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9, on a multi-ingredient oral supplement on dry eye symptoms and tear volume.
Read More
ARVO 2024: Post-hoc analysis of GOBI and MOJAVE trials for perfluorohexyloctane
May 7th 2024John Sheppard, MD, MSc, FACs, sat down to discuss post-hoc analysis of 2 FDA registration trials for perfluorohexyloctane, GOBI and MOJAVE, at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
Read More
ARVO 2024: Clinical evaluation of a novel lipid-containing eye drop
May 7th 2024Eric Donnenfeld, MD, sat down to discuss presentations on the novel new artificial tear, Blink Triple Care, about its efficacy in a non-controlled trial as well as comparison to the Classic Blink at this year's ARVO meeting held in Seattle, Washington, from May 5 to May 9.
Read More
ARVO 2024: Deep learning model for GA segmentation, adaptable to SS-OCT and SD-OCT data
May 5th 2024At this year's ARVO meeting, Qinqin Zhang, PhD, presented a poster titled "A unified deep learning model for geographic atrophy segmentation: Adaptable to SS-OCT and SD-OCT data with multiple scan patterns." At the conference she gave Ophthalmology Times an overview.
Read More
ARVO 2024: 36-month data from the GALE study of pegcetacoplan
May 5th 2024At this year's ARVO meeting, Ash Abbey, MD, Director of clinical research at Texas Retina Associates, presented 36-month data from the GALE study of pegcetacoplan for the treatment of dry age-related macular degeneration specifically geographic atrophy.
Read More
Aurion Biotech completes dosing of all subjects in Phase 1/2 CLARA trial
May 1st 2024The trial is evaluating AURN001, a combination cell therapy product comprised of neltependocel (allogeneic human corneal endothelial cells [CECs]) and Y-27632 for the treatment of corneal edema secondary to corneal endothelial dysfunction.
Read More